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The most common manifestations of neonatal lupus ery-
thematosus (NLE) are cutaneous lupus and congenital heart 
block. Autoantibodies to Ro/SSA occur in almost all cases of 
NLE. The autoantibody response to Ro/SSA is complex, and 
antibodies may be detected to 60-kD Ro/SSA, 52-kD Ro/ 
SSA, La/SSB, and U 1 ribonuclear protein in anti-Ro/SSA-
positive sera. Which of these anti-Ro/SSA-related autoan-
tibody specificities are important in the clinical expression of 
NLE is not conclusively established. 
We examined the autoantibody specificities in 20 maternal 
NLE sera to determine whether autoantibody specificities 
correlate with the clinical findings and to evaluate the rela-
tive importance of autoantibodies to the different Ro/SSA-
associated proteins. Autoantibodies were examined using 
inununodiffusion, immunoblotting, and enzyme-linked im-
rnunosorbent assay. Eleven babies had NLE skin disease, 11 
had heart block, and two had both skin disease and heart 
T he term neonatal lupus erythematosus (NLE) has been used to describe a clinical syndrome consisting char-acteristically of congenital heart block or subacute cu-taneous lupus lesions, occurring in babies whose mothers have autoantibodies [1]. In most cases, the 
maternal autoantibodies have been anti-Ro/SSA or anti-La/SSB, 
but there have been a few cases of NLE skin disease in which the 
autoantibodies were anti-UI ribonuclear protein (UtRNP) [2]. 
The autoantibody response to RolSSA is complex, and it is typi-
cal for more than one protein to be bound by autoantibodies in 
anti-Ro/SSA-positive sera. The originally described RolSSA pro-
tein is a ribonuclear protein of 60 kD [3,4]. About half of anti-Rol 
I SSA precipitin-positive sera contain antibodies both to the 60-kD 
I protein and to a 52-kD protein referred to as 52-kD RolSSA [5 - 7]. 
The coding sequences for the 52-kD and the 60-kD proteins are 
, known, and the two cDNAs share no significant regions of homo 1-
ogy [8,9]. Approximately 30% of anti-Ro/SSA precipitin-positive 
sera also contain precipitating antibodies to the La/SSB protein, a 
47-kD ribonuclear protein involved in RNA transcription [10-12]. 
Approxi~~tely 15% ?f afoLti-Ro/SSA precipitin~positive sera c?n-
tain preClpltatmg antibodies to the UtRNP sphceosome protems, 
and this subset of anti-RojSSA sera is distinct from the subsets that 
bind La/SSB and 52-kD RolSSA [6,10]' Which of the anti-Rol 
SSA-related autoantibody specificities are important in the clinical 
expression of NLE is not established. 
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block. All 20 maternal sera had antibodies to 60-kD Ro/SSA. 
Eighteen of the 20 had antibodies to 52-kD Ro/SSA, nine 
had antibodies to La/SSB, and one had antibodies to U 1 ri-
bonuclear protein. The prevalence of anti-La/SSB was the 
same in the skin-disease and heart-block subsets of NLE. 
Titers of anti-60-kD Ro/SSA were significantly (p < 0.02) 
lower in NLE skin disease maternal sera than in the NLE 
heart-block maternal sera. 
These results point out the importance of 60-kD Ro/SSA 
as a potential target in NLE. We speculate that the lower 
titers of anti - 60-kD Ro/SSA in the sera from mothers of 
babies with skin disease may be due to substantial deposition 
of antibodies in the mothers' and babies' skin, leading to 
lower circulating titers, or may reflect a lower threshold for 
development of skin disease than for heart block. Key words: 
autoantibodies/neonatal lupus erythematosus/ anti-RoISSA/ anti-
La/SSB.] Im/est DermatoI102:963-966, 1994 
Infants with NLE tend to have heart block or skin disease, but not 
both, although about 10% ofNLE infants have had coexistent heart 
and skin disease [1] . Also, mothers who have had a baby with NLE 
are likely, if they have another affected infant, to have that infant 
affected in the same way as was the first infant. That is, a mother of a 
baby with heart block will, if she has another affected child, proba-
bly have another baby with heart block [13]. The factors determin-
ing whether babies develop heart block or develop skin disease are 
not yet known. 
We have examined the autoantibody specificities in 20 maternal 
NLE sera to determine whether autoantibody profiles correlate 
with clinical findings and to determine which of the anti-Ro/SSA-
associated antibodies are likely to be most important in the patho-
genesis of NLE. 
MATERIALS AND METHODS 
Patient Group Sera were obtained from mothers of babies with neonatal 
lupus. The clinical selection was based on the identification of disease in the 
child; that is, sera were not pre-selected to be from mothers with rheumatic 
or skin disease. Sera were obtained in accordance with Institutional Review 
Board guidelines. 
Antibody Studies Immunodiffusion was performed according to a stan-
dard protocol [3,14]. Calf thymus extract was used as the antigen source. 
Test sera were compared to standard reference sera. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotting were done •. ccording to the protocol of Buyon 
and c?-workers, using rrotein extract derived from the human T -cellieuke-
mta lme MOLT -4 [15 . Antibody binding was detected with a protein A or 
anti-human IgG alkaline phosphatase conjugate, developed with a color 
substrate. 
EllZyme-linked immunosorbent assays (ELISA) were performed accord-
ing to standard techniques, measuring reactivity with affinity-purified na-
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Table I. Clinical Findings in Neonatal Lupus Patients and Autoantibodies in Maternal Sera 
aRo a 60-kD Ro a 60-kD Ro a 52-kD Ro a 52-kD Ro aLa aLa aLa 
Clinical Immuno- Immuno- ELISA in Immuno- ELISA in Irnmuno- Immuno- ELISA in 
Patient Findings' diffusion blotting Unitsb blotting Unitsb diffusion blotting Unitsb 
1 S + + 160 + 420 
2 S + + 770 + 270 + + 120 
3 S + + 620 + 63 
4 S + + 5,200 + 420 
5 S + + 1,700 + 380 + + 52 
6 S + + 2,900 + 390 
7 S + 480 + + 34 
8 S,L + + 680 + 350 + + 62 
9 S,L,T 530 + + 65 
10 S,H + + 430 5 
11 S,H + 5,800 + 700 
12 H + + 3,700 68 + + 120 
13 H + + 12,000 + 120 
14 H + + 2,300 + 5,400 + + 120 
15 H + + 6,800 + 1,500 
16 H + + 1,300 + 13 
17 H + + 10,000 + 1,200 
18 H + + 1,100 + 1,100 + + 350 
19 H + + 2,700 + 4,500 + + 61 
20 H,L + + 830 + 36 
• S, skin disease; H, heart block/heart disease; L, liver disease; T, thrombocytopenia. Minus, autoantibodies were not detected in the assay. 
• The units listed above should be multiplied by 10'. For example, the value "700" represents 7,000,000 units. 
tive bovine 60-kD Ro/SSA [16]. with native bovine La/SSB [17], with 
native bovine U,RNP [18], and with the full-length recombinant human 
52-kD Ro/SSA expressed in Escherichia coli [8]. ELISA activity for the re-
combinant protein was adjusted by subtraction of optical density values of 
patient sera that bound to proteins expressed by E. coli containing the expres-
sion vector without the 52-kD eDNA insert. Serial dilutions of sera were 
tested, and units of activity calculated using a reference serum to generate a 
standard curve. According to previous analyses, sera segregate into low- and 
high-titer groups. For the anti-60-kD, anti-La/SSB, and anti-U,RNP 
ELISAs, high-titer sera have at least 100,000 units. For the anti-52-kD 
ELISA, high-titer sera have at least 250,000 units. Data were analyzed using 
JMP software (SAS Institute, Cary, NC). Less than 10% of normal sera 
contain low titers of autoantibodies in the anti-60-kD Ro/SSA, anti-52-
kD Ro/SSA, and anti-La/SSB ELISAs. No normal sera have been found 
with autoantibodies to U,RNP in the ELISA. 
RESULTS 
Clinical Findings The clinical findings of NLE are listed in 
Table I. Eleven babies had skin disease (Patients 1-11), and 11 had 
heart disease (Patients 10-20). Three babies (Patients 15, 16, and 
20) died in the perinatal period due to heart failure. Two babies had 
both skin and heart disease (Patients 10 and 11). Three had choles-
tatic liver disease (Patients 8, 9, and 20), and one had thrombocyto-
penia (Patient 9) . 
Antibody Profiles All 20 maternal sera had antibodies to 60-kD 
Ro/SSA (Table I). Eighteen of20 had antibodies to 52-kD Ro/SSA, 
and nine of 20 had antibodies to La/SSE. The presence of anti-La/ 
SSB was not specific for any clinical subset of NLE. Anti-La/SSB 
antibodies were present in five of 11 sera from mothers of babies 
with skin disease ("skin disease sera"), four of 11 mothers of babies 
with heart block ("heart disease sera"), and two of three mothers of 
babies with liver disease. Only one of the 20 sera (Patient 19) had 
low-titer anti-U,RNP antibodies, detected in ELISA but not im-
munodiffusion. In addition, one serum (Patient 1) had anti-Sm au-
toantibodies detected in ELISA but not immunodiffusion, and one 
serum (Patient 13) had high-titer antibodies to native DNA, de-
tected by the Crithidia /uci/iae assay. 
The prevalence of antibodies to 52-kD Ro/SSA was increased in 
the NLE maternal sera grou£, compared to the prevalence previ-
ously reported in 43 anti-Ro/SSA-positive sera from systemic lupus 
erythematosus and Sjogren's syndrome patients (80% versus 51 % in 
immunoblotting, p = 0.03) [19]. The prevalence of antibodies to 
La/SSB in the NLE maternal sera was not significantly different 
from the prevalence previously reported in 133 anti-Ro/SSA-
positive sera (45% versus 29% in immunodiffusion, p = 0.14) [10]. 
Antibody Titers The distribution of the levels of different forms 
of anti-Ro/SSA antibodies as determined in ELISA are shown in Fig 
1 and 2. The skin-disease sera had lower titers of anti-60-kD Roj 
SSA in ELISA than did the heart-disease sera (p = 0.019). For the 
purposes of comparing the two groups, the two sera from mothers 
of babies who had both skin disease and heart block were excluded 
from analysis. If these two sera were included as skin-disease sera, 
comparing babies with skin disease to those without skin disease, 
the groups were still significantly different, p = 0.029. If the two 
sera were included as heart disease sera, comparing babies with heart 
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Figure 1. Anti-60-kD Ro/SSA ELISA results, displayed as logarithm of 
units. Bars, mean ± SEM for the two groups. The nine maternal NLE heart-
block sera have significantly higher titers of antibodies to native 60-kO 
Ro/SSA than do the nine maternal NLE skin disease sera (p < 0.02). 











'" ! I 












Figure 2. Anti-52-kD RolSSA ELISA results, displayed as logarithm of 
units. Sera containing anti-52-kD antibodies are shown as closed squares, 
whereas sera having no detectable anti - 52-kD antibodies are shown as ope/! 
squares. The bars represent the mean ± SEM for the two groups. There is no 
significant difference between the nine maternal NLE heart-block sera and 
the nine maternal NLE skm disease sera (p = 0.19). 
disease to those without heart disease, the groups were significantly 
different, p = 0.032. If all sera from mothers of babies with more 
than one manifestation ofNLE were excluded, the skin- and heart-
disease sera remained significantly different, p = 0.032. 
The skin-disease sera had a lower average titer of anti - 52-kD 
Ro/SSA in ELISA, but the difference between the skin-disease and 
the heart-disease sera was not significant (p = 0.19). 
There was no significant difference between the titers of anti-La/ 
SSB in the skin-disease and the heart-disease sera (p = 0.9, Table I). 
When the 11 anti-La/SSB - negative sera were excluded from anal-
ysis, the difference between the groups was still not significant 
(p = 0.09). Among the anti-La/SS~ - positive .sera, the titer in the 
skin disease sera, expressed as loganthm of umts, was 5.79 ± 0.09 
(mean ± SEM), whereas the heart-disease group titer was 6.12 ± 
0.16. 
corn.parison of Assays for Anti-Ro/ SSA and Anti-La/ 
SSB All but one serum had an anti-Ro/SSA precipitin line in 
I imITlunodiffusion. Seventeen of20 sera had anti-60-kD Ro/SSA in 
I imITlunoblotting, and 20 of20 had high-titer anti-60-kD Ro/SSA 
in ELISA. Immunoblotting fai led to detect anti-60-kD Ro/SSA in 
1 three sera that had high titers in the ELISA. Sixteen of 20 sera had 
! anti - 52-kD Ro/SSA in immunoblotting. Immunoblotting failed 
I to detect anti-52-kD Ro/SSA in two sera that had low titers in 
j ELISA. IITlmunodiffusion, immunoblotting, and ELISA results corre-
I, sponded exactly for anti-La/SSB (Table I) . Five sera (Patients 3,11, 13, 15, and 20) had faint bands at approximately 48 kD in immun-i obi otting. The 48-kD band was not interpreted as definitely repre-
senting La/SSB, because binding to the La/SSB degradation prod-
ucts, observed in all the clearly anti-La/SSB - positive sera, was not 
detected. In addition, these five sera did not have detectable anti-
La/SSB in ELISA. 
DISCUSSION 
The significance of NLE goes beyond its immediate impact on 
affected families. NLE is also important as an experiment of nature 
providing information about the pathogenesis oflupus erythemato-
sus. In this experiment, autoantibody production is segregated from 
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the development of disease, as the autoantibodies present in affected 
babies are passively acquired from the mother during gestation. In 
most cases described, the autoantibodies detected are anti-Ro/SSA. 
The observation that disease activity resolves by the time that ma-
ternal autoantibodies are eliminated from the baby's circulation 
provides strong circumstantial evidence that the autoantibodies 
have a role in the disease process. 
In this study, we show that the most consistent anti-Ro/SSA 
response is to the 60-kD protein, with antibodies to 60-kD Ro/SSA 
being present in all sera. In almost all cases, the antibodies are of the 
anti-Ro/SSA subset that bind both the 60-kD and the 52-kD pro-
teins. Antibodies to UIRNP were detected in only one of the 20 
sera. The anti-UIRNP antibodies in that serum were present in a 
low titer, were detectable only in ELISA, and coexisted with high-
titer antibodies to 60-kD RoISSA, 52-kD Ro/SSA, and La/SSB. 
Antibodies to cal reticulin, a calcium-binding protein of the endo-
plasmic reticulum, have also been described in anti-Ro/SSA sera 
[20,21 ). Our studies do not address the autoantibody response to 
caIreticulin and its relationship to neonatal lupus. 
In one previous study of NLE maternal sera, the predominant 
antibody responses detected in 20 sera were to La/SSB (90%) and 
52-kD RolSSA (75%), with antibodies to 60-kD RolSSA being 
found in only 45% [22). The low prevalence of antibodies to 60-kD 
RolSSA is probably explained by the assays used . Antibody binding 
to 60-kD Ro/SSA is, in many sera, profoundly diminished by dena-
turation of the protein [19). Optimal detection of antibodies to 
60-kD Ro/SSA is achieved with assays that use the protein in its 
native conformation, as is the case for our ELISA and for immuno-
diffusion. Immunoblotting, which is typically done with dena-
tured, reduced protein, is not an optimal assay for detecting anti-
bodies to 60-kD Ro/SSA. In addition, some anti-Ro/SSA sera bind 
much more avidly to human 60-kD Ro/SSA than to other species' 
Ro/SSA such as murine or bovine 60-kD Ro/SSA, and human 
antigen must be used in special cases to detect anti- 60-kD Ro/SSA 
[23]. In the experience of one of the authors, there has never been a 
serum found with antibodies to La/SSB that does not also have 
antibodies to 60-kD Ro/SSA (M. Reichlin, unpublished data). 
Thus, we predict that the NLE sera in the study described above had 
a high prevalence of antibodies to 60-kD Ro/SSA. Given that all or 
almost all anti-La/SSB sera also contain antibodies to 60-kD Ro/ 
SSA, although only a subset of anti-60-kD Ro/SSA sera contain 
antibodies to La/SSB, it would follow that anti-La/SSB should not 
be as prevalent in NLE as is anti-60-kD Ro/SSA. 
Another difference between our study and the previous one cited 
is the prevalence of antibodies to La/SSB. We found anti-La/SSB in 
45% of NLE maternal sera. Another group, in a review article, 
described antibodies to La/SSB in 11 of 21 (52%) maternal NLE 
skin-disease sera, and six of 10 (60%) maternal heart block sera [13). 
These studies together indicate that antibodies to La/SSB are com-
mon but not universal in NLE, and do not confer a predilection for 
either heart block or skin disease. 
The autoantibody response to 52-kD Ro/SSA, unlike that to 
60-kD Ro/SSA, appears to be primarily to epitofes that are present 
on the denatured or recombinant molecule [19J, and ELISA with 
recombinant 52-kD Ro/SSA should yield optimal detection of 
these autoantibodies. The lack of detectable anti-52-kD RolSSA 
antibodies in the ELISA in two NLE skin disease sera suggests that 
antibodies to 52-kD Ro/SSA are not absolutely necessary for NLE 
skin disease to occur. However, anti - 52-kD antibodies were de-
tected in all the heart-block maternal sera and could conceivably be 
required for the development of heart block. It has been shown 
previously that reactivity of denatured 52-kD Ro/SSA represents a 
cross reaction with autoantibodies directed to the native 60-kD 
Ro/SSA molecule [24). The high prevalence of antibodies to 52-kD 
RolSSA in the NLE group may be an indication that a shared epi-
tope or epitopes between denatured 52-kD and native 60-kD Ro/ 
SSA are disease related. The definitive explication of the role of 
anti-52-kD Ro/SSA in heart block and the frequent coexistence of 
anti-60-kD Ro/SSA and anti-52-kD Ro/SSA in NLE sera await 
further study. 
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The assays most valuable for verifying the diagnosis of NLE are 
immunodiffusion and native 60-kD Ro/SSA ELISA, because all sera 
had Ro/SSA and/or La/SSB precipitins, and all sera had high titers 
of antibodies to native 60-kD Ro /SSA in ELISA. Immunoblotting is 
not reliable for detecting high titers of anti-60-kD Ro/SSA, be-
cause of the importance of conformational epitopes. Immunoblot-
ting results correlate well with ELISA results in the anti - 52-kD 
Ro/SSA assays, but ELISA is more sensitive. Immunodiffusion, im-
munoblotting, and ELISA are equally useful for detecting high 
titers of anti-La/SSB. No low-titer anti-La/SSB sera were found in 
our sample. 
The reasons why some babies develop skin disease, whereas 
others develop heart disease, are not known. Our results indicate 
that titers of antibodies could be a factor involved in determining 
organ predilection. The NLE subset with skin disease had signifi-
cantly lower circulating titers of anti-60-kD Ro/SSA in the mater-
nal sera than did the subset with heart disease. There is a possibility 
that factors other than the clinical subset of NLE in the baby could 
account for the difference between the groups. However, when we 
considered possible differences in the maternal groups with regard 
to maternal disease, treatment, and time from delivery to the time 
the serum sample was collected, we could not find any significant 
differences between the groups. Nor could we find significant dif-
ferences within a group between the higher-titer and the lower-titer 
sera. We offer two hypotheses, not mutually exclusive, based on our 
results. One is that higher titers of circulating antibodies increase 
the risk for heart disease. The other is that the sera from mothers of 
babies with skin disease may contain antibodies that have a very 
high affinity for the skin and deposit in the mothers' and babies' skin 
in substantial quantities. The vast size of the skin may render it 
effective in lowering the circulating amount of antibodies. At the 
present time, data are not available to evaluate the latter hypothesis . 
In summary, the results of detailed autoantibody analysis of 20 
maternal NLE'sera point out the importance of 60-kD Ro/SSA as a 
potential target in NLE. Antibodies to 52-kD Ro/SSA typically but 
not invariably coexist with anti-60-kD Ro/SSA in NLE maternal 
sera. Although autoantibody specificities are similar in the different 
clinical subsets, sera from mothers of babies with skin disease con-
tain lower titers of anti-60-kD Ro/SSA than do sera from mothers 
of babies with heart disease. 
We ack/lOwledge the tecJlllical assistance of Farideh Movafagh, Cynthia Pickens, 
Charles M. Roberts, David Rice, Sandra Long, Craig Wasson, Maria/llle Wolfsoll 
Reichlitl, and Elizabeth Taylor-Albert. 
This work was supported in part by a grant from the Departllletlt of Veterans 
Affairs, funditlgfrom the Oklahoma Cellter for Molecular Medicine atld the Okla-
homa Celller for the Advancement of Scie/lCe and Tecilllology, and NIH grams AR 
31133, Al 21568, and AR 32214. 
REFERENCES 
1. Lee LA: Maternal autoantibodies and pregnancy - II: the neonatal lupus syn-
drome. Bail/ieres Cli" RheumotoI4:69-84, 1990 
2. Provost 11. Watson R. Gammon WR. Radowsky M. Harley JB. Reichlin M: 
The neonatal lupus syndrome associated with U,RNP (nRNP) antibodies. 
N Ellgl] Med 316:1135-1138.1987 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
3. Clark G. Reichlin M. Tomasi TB: Characterization of a soluble cytoplasmic 
antigen reactive with sera from patients with systemic lupus erythematosus. 
] Irnm'lIJoll 02: 117 - 122. 1969 
4. Lerner MR. Boyle JA. Hardin JA. Steitz JA: Two novel classes of small ribonu-
cleoproteins detected by antibodies associated with lupus erythematosus. Science 
211:400-402.1981 
5. Ben-Cherrit E. Chan EKL. Sullivan KF. Tan EM: A 52-kD protein is a novel 
component of the SS-A/Ro antigenic particle. ] Exp Med 167:1560- 1571. 
1988 
6. Itoh Y. Rader MD. Reichlin M: Heterogeneity of the Ro/SSA antigen and au-
toanti-Ro/SSA response: evidence of the four antigenically distinct forms. Cli" 
Exp Immllllo/81:45-51. 1990 
7. Ben-Chetrit E. Fox RI. T an EM: Dissociation of immune responses to the SS-A 
(Ro) 52-kD and 60-kD polypeptides in systemic lupus erythematosus and Sjo-
gren's syndrome. Arthritis Rheum 33:349 - 355. 1990 
8. Itoh K. Itoh Y. Frank MD: Protein heterogeneity in the human Ro/SSA ribonu-
cleoproteins. The 52- and 60-kD autoantigens are encoded by separate genes. 
] Clill Invest 87:177 -186. 1991 
9. Chan EK. Hamel JC. Buyon JP. Tan EM: Molecular definition and sequence 
motifs of the 52-kD component of human SS-A/Ro autoantigen.] Cli" Ittvest 
87:68- 76. 1991 
10. Reichlin M. Harley JB: Detection by ELISA of antibodies to small RNA protein 
particles in systemic lupus erythematosus patients whose sera lack precipitins. 
Tratts Asso, Am Physicians 99:161-171. 1986 
11. Chambers JC. Kenan D. Martin BJ. Keene JD: Genomic structure and amino acid 
sequence domains of the human La autoantigen.] Bioi Chem 263:18043-
18051. 1988 
12. Gottlieb E. Steitz JA: Function of the mammalian La protein: evidence for its 
action in transcription termination by RNA polymerase III . EMBOJ 8:851-
861. 1989 
13. Provost 11. Watson R: Anti-Ro(SS-A) HLA-DR3-positive women: the interre-
lationship between some ANA negative. SS. SCLE. and NLE mothers and 
SS/LE overlap female patients.] In vest Dermato/l00:14S-20S. 1993 
14. Mattioli M. Reichlin M: Heterogeneity of RNA protein antigens reactive with 
sera of patients with systemic lupus erythematosus. Artl"itis Rhellmatol 
17:421-429. 1974 
15. BuyonJP. Slade SG. Chan EKL. Tan EM. Winchester R: Effective separation of 
the 52 kDa SSA/Ro polypeptide from the 48 kDa SSB/La polypeptide by 
altering conditions of polyacrylamide gel electrophoresis. ] Immllttol Meth 
129:207 - 21 O. 1990 
16. Yamagata H. Harley JB. Reichlin M: Molecular properties of the Ro/SSA antigen 
and enzyme-linked immunosorbent assay for quantitation of antibody.] Clill 
Illvest 74:625-633.1984 
17. Harley JB. Yamagata H. Reichlin M: Anti-La/SSB antibody is present in some 
normal sera and is coincident with anti-Ro/SSA precipitins in systemic lupus 
erythematosus.] Rhellmatolll:309 -3 14. 1984 
18. Reichlin M: Measurement of antibodies to Sm and nRNP by ELISA: clinical and 
serological correlations. In: Sharp RKaGC (ed.). Mixed Com,ective Tissue Disease 
and Anti-Nuclear Antibodies. Elsevier. 1987. pp 85-96 
19. Itoh Y. Reichlin M: Autoantibodies to the Ro/SSA antigen are conformation 
dependent. I: Anti-60 kD antibodies are mainly directed to the native protein; 
anti - 52 kD antibodies are mainly directed to the denatured protein. Autoim-
munity 14:57 -65.1992 
20. McCauliffe DP. Zappi E. Lieu T-S. Michalak M. Sontheimer RD. CapraJD: A 
human Ro/SS-A autoantigen is the homologue of calreticulin and is highly 
homologous with onchocercal RAL-l antigen and an Aplysia "memory mole-
cule."] Clill Irwest 86:332 - 335.1990 
21. Lieu TS. Newkirk MM. Arnett FC. et al: A major autoepitope is present on the 
amino terminus of a human SS-A/Ro polypeptide.] Alltoimm'lIJ 2:367 -374. 
1989 
22. Buyon JP. Ben CEo Karp S. et al: Acquired congenital heart block. Pattern of 
maternal antibody response to biochemically defined antigens of the SSA/Ra-
SSB/La system in neonatal lupus. ] Clin In vest 84:627 -634.1989 
23. Reichlin M. Reichlin MW: Autoantibodies to the Ro/SS-A particle react prefer-
entially with the human antigen.] Autoimmllll 2:359 - 365. 1989 
24. Itoh Y. Itoh K. Frank MD. Reichlin M: Autoantibodies to the Ro/SSA autoanti-
gen are conformation dependent II: antibodies to the denatured form of 52 kD 
Ro/SSA are a cross reacting subset of antibodies to the native 60 kD Ro/SSA 
molecule. Autoimm'lIIity 14:89-95. 1992 
